EndLyz Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EndLyz Therapeutics is a private, pre-clinical biotech emerging from stealth to tackle Parkinson's disease and related dementias by targeting lysosomal dysfunction. The company is advancing a first-in-class portfolio of small molecules against two genetically validated targets, ATP13A2 and ATP10B, with an initial focus on genetic subsets of Parkinson's. Backed by notable venture investors including SV Health Investors, AbbVie Ventures, and Oxford Science Enterprises, EndLyz is positioned to pursue a precision medicine approach with potential expansion into broader sporadic neurodegenerative indications.

Parkinson's DiseaseNeurodegenerative DiseasesDementia

Technology Platform

Small-molecule drug discovery platform focused on modulating lysosomal function via specific transporter targets (ATP13A2 and ATP10B) to treat neurodegenerative diseases.

Opportunities

The primary opportunity is addressing the vast, unmet need for disease-modifying therapies in Parkinson's disease and other dementias.

A precision medicine approach starting with genetic subsets offers a de-risked path to clinical proof-of-concept before expanding into the much larger sporadic patient populations.

First-in-class success could command a multi-billion dollar market.

Risk Factors

High scientific risk in translating novel lysosomal biology into effective human therapeutics, including the challenge of discovering brain-penetrant small molecules against difficult transporter targets.

Significant financial risk as a pre-revenue company reliant on future venture funding rounds to advance costly clinical development.

Competitive Landscape

Competition is intense in Parkinson's disease from both symptomatic and novel disease-modifying approaches. While ATP13A2 and ATP10B are novel targets, other companies are pursuing related lysosomal pathways (e.g., GCase activators). Large pharma and biotech are active in neurodegeneration, creating a race for clinical validation of new mechanisms.

More companies in United Kingdom →